Market Research Logo

rhEPO Market in China 2016-2020

About the Recombinant Human Erythropoietin (rhEPO) Market in China

Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the normal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the normal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases.

Technavio’s analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on application of rhEPO:

  • End-stage renal disease (ESRD)
  • Cancer
  • Human immunodeficiency virus (HIV)
  • Wounds and neural disease
Technavio's report, Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • 3S Bio
  • Shanghai Chemo
  • Chengdu Di’ao
  • NCPC Genetech
  • Kyowa Hakko Kirin
  • Shandong Kexing
Other prominent vendors
  • Ahua Pharmaceutical
  • Biosidus
  • Dragon Pharma
  • Huaxin High Biotechnology
  • Kehua Bio-Engineering
  • LG Life Sciences
  • Shenzhen Sai Bao Er Bio-Pharmaceutical
  • Sihuan
  • Shenyang Sunshine Pharmaceutical
  • Uni-Bio Science Group
  • Wanbang Biochemical Pharmaceuticals
Market driver
  • Increase in chronic kidney disease (CKD) and dialysis patient population
  • For a full, detailed list, view our report
Market challenge
  • Complex manufacturing process
  • For a full, detailed list, view our report
Market trend
  • Exploitation of novel therapeutic areas
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020

Technavio recognizes the following companies as the key players in the recombinant human erythropoietin (rhEPO) market in China: 3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genetech, Kyowa Hakko Kirin, and Shandong Kexing.

Other Prominent Vendors in the market are: Ahua Pharmaceutical, Biosidus, Dragon Pharma, Huaxin High Biotechnology, Kehua Bio-Engineering, LG Life Sciences, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan, Shenyang Sunshine Pharmaceutical, Uni-Bio Science Group, and Wanbang Biochemical Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “A major trend which will boost market growth is the exploitation of novel therapeutic methods. The use of EPO has expanded to therapeutic areas other than for the treatment of anemia. For instance, recombinant EPO therapy is used to treat cardio-renal anemia syndrome. Use of EPO has shown an improvement in left and right ventricular systolic function in such patients with the reduction in cardiac remodeling, brain natriuretic peptide (BNP) levels, and hospitalization rate. Apart from this, with the discovery of EPO receptors in non-erythroid tissues, EPO has been investigated as a novel therapeutic agent in diseases and therapeutic conditions, including spinal cord injury, depression, diabetes, and as an immunomodulating agent.”

According to the report, a key growth driver is the increase in CKD and dialysis patient population. An increase in the anemic population is expected to boost the market growth as EPO drugs are used as a treatment option for anemia. Anemia can be caused due to a number of diseases such as kidney disease, cancer, and HIV. In individuals with CKD, anemia develops due to the dysfunction of the kidneys. In this condition, the levels of EPO are low, which results in the development of anemia. Also, deficiency of iron, vitamin B12, and folic acid, which are essential for forming hemoglobin by RBCs, can result in anemia. The condition is aggravated in individuals undergoing dialysis; 80% of the individuals on dialysis are on EPO therapy to treat anemia

Further, the report states that one challenge that could restrict market growth is the complex manufacturing process. Unlike small molecule drugs, biologics are prepared from living organisms. Hence, the production process involved is complicated and time-consuming.



Companies Mentioned

3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus, Dragon Pharma, Huaxin High Biotechnology, Kehua Bio-Engineering, LG Life Sciences, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan, Shenyang Sunshine Pharmaceutical, Uni-Bio Science Group, Wanbang Biochemical Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Erythropoietin: An overview
    • Table Historical timeline of EPO development
    • Clinical uses of EPO
    • Abusive uses of EPO
    • Risks of EPO use
  • Global erythropoietin market
    • Table Globally approved EPO biosimilars
  • China: Country snapshot
    • Social and economic conditions
      • Table China GDP 2010-2014 ($ trillions)
      • Table China: Healthcare expenditure 2009-2013 (% of GDP)
    • Healthcare reforms
      • Table Healthcare reforms in China
    • Healthcare infrastructure
  • Opportunities for pharmaceutical vendors in China
    • Table China pharmaceutical market overview: SWOT analysis
    • Major pharmaceutical vendors in China
    • Opportunities for global and local vendors
      • Table New drug approval (NDA) review process in China
      • Table New drug approval process in China
      • Table Drug registration classification and requirements in China
  • Biopharmaceutic al market in China
    • Table Notable achievements in biopharmaceutical industry in china
    • Biosimilar market in China
    • Market size and forecast
      • Table Biopharmaceutical market in China 2015-2020 ($ billions)
  • Market landscape
    • Market overview
      • Table rhEPO market in China in global biopharmaceutical market 2015
    • Market size and forecast
      • Table rhEPO market in China 2015-2020 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by end-user
    • Table rhEPO market in China by distribution channels 2015
    • Hospitals
      • Table Share of domestic rhEPO drugs in hospitals in China 2015
    • Retail pharmacies
  • Market segmentation by application
    • ESRD
    • Cancer
    • HIV
    • Wounds and neural disease
  • Drug pricing and reimbursement in China
    • Market-driven drug pricing strategy
      • Table Changes in the drug pricing system before and after 2015 reforms
    • Scrutinization of illegal pricing of drugs
  • Pipeline portfolio
    • Table Pipeline portfolio: rhEPO market in China
    • NuPIAO
    • Uni-EPO-Fc
    • PEG-EPO
  • Market drivers
    • Increase in CKD and dialysis patient population
    • Growth in prevalence of cancer
    • Support for local manufacturers
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complex regulatory framework and approval process
    • Complex manufacturing process
    • Development of alternative therapies
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Penetration of rhEPO drugs in grade I and II hospitals
    • Exploitation of novel therapeutic areas
    • Initiation of R&D activities by local/domestic vendors
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2015
    • 3S Bio
      • Table 3S Bio: YoY revenue comparison of EPIAO 2014-2015 ($ millions)
      • Table 3SBio: Key takeaways
    • Shanghai Chemo
      • Table Shanghai Fosun: YoY revenue and growth rate of blood system products 2013-2015 ($ millions)
      • Table Shanghai Chemo: Key takeaways
    • Chengdu Di'ao
      • Table Chengdu Di'ao: Key takeaways
    • NCPC Genetech
      • Table NCPC Genetech Biotechnology: Key takeaways
    • Kyowa Hakko Kirin
      • Table Kyowa Hakko Kirin: Key takeaways
    • Shandong Kexing
      • Table Shandong Kexing: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report